Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esaxerenone Phase 2 Study in Japanese Patients with Type 2 Diabetes and Microalbuminuria
NCT02345057Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of esaxerenone in diabetic nephropathy (DN) (5 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change from baseline in urinary albumin to creatine ratio at 12 weeks. Started Jan 2015; status: completed.
02
Drugs
esaxerenone
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT02345057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02345057.